Metsera, Inc. Common Stock (MTSR) - Total Assets
Based on the latest financial reports, Metsera, Inc. Common Stock (MTSR) holds total assets worth $639.66 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Metsera, Inc. Common Stock - Total Assets Trend (2022–2024)
This chart illustrates how Metsera, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. Also see Metsera, Inc. Common Stock stock valuation for the company's overall valuation and market capitalisation.
Metsera, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2024)
Metsera, Inc. Common Stock's total assets of $639.66 Million consist of 79.6% current assets and 20.4% non-current assets. Review Metsera, Inc. Common Stock (MTSR) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 78.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $68.52 Million | 15.2% |
| Goodwill | $21.89 Million | 4.9% |
Asset Composition Trend (2022–2024)
This chart illustrates how Metsera, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Metsera, Inc. Common Stock (MTSR) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Metsera, Inc. Common Stock's current assets represent 79.6% of total assets in 2024, a decrease from 100.0% in 2022.
- Cash Position: Cash and equivalents constituted 78.2% of total assets in 2024, down from 100.0% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 19.0% of total assets, an increase from 0.0% in 2022.
- Asset Diversification: The largest asset category is intangible assets at 15.2% of total assets.
Metsera, Inc. Common Stock Competitors by Total Assets
Key competitors of Metsera, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Metsera, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.26 | 3.81 | 3.81 |
| Quick Ratio | 5.26 | 3.81 | 3.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $435.77 Million | $56.63 Million | $56.63 Million |
Metsera, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Metsera, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.30 |
| Latest Market Cap to Assets Ratio | 9.14 |
| Asset Growth Rate (YoY) | 167.1% |
| Total Assets | $450.99 Million |
| Market Capitalization | $4.12 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Metsera, Inc. Common Stock's assets at a significant premium (9.14x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Metsera, Inc. Common Stock's assets grew by 167.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Metsera, Inc. Common Stock (2022–2024)
The table below shows the annual total assets of Metsera, Inc. Common Stock from 2022 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $450.99 Million | +167.11% |
| 2023-12-31 | $168.84 Million | +1027.11% |
| 2022-12-31 | $14.98 Million | -- |
About Metsera, Inc. Common Stock
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to re… Read more